TITLE

Variabilidad en la determinación del estado de HER2 por inmunohistoquímica en Chile

AUTHOR(S)
Contreras-Melendez, Luis; Piottante-Becker, Antonio; Contreras-Seitz, María; Garmendia-Flores, María; Levican-Asenjo, Jorge
PUB. DATE
January 2013
SOURCE
Revista Española de Patología;ene-mar2013, Vol. 46 Issue 1, p33
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background: HER2 gene status in breast cancer is an important prognostic marker and therefore must be assessed using an accurate technique. Background: HER2 gene status in breast cancer is an important prognostic marker and therefore must be assessed using an accurate technique. Patients and methods: We analyzed 221 biopsies of invasive breast cancer from 41 laboratories nationwide, assessing HER2 status by Fluorescent In Situ Hybridization (FISH). Analysis was possible in 201 of the biopsies. The HER2 status was determined by IHC and FISH in a standardized way in accordance with the recommendations of the American Society of Clinical Oncology and the College of American Pathologists (ASCO/CAP). The results were compared with IHC reports from different laboratories Results: The variability of the assessment of HER2 status in the 41 laboratories is similar to that reported in the literature. In comparison with standardized IHC technique, variability was 19.7% but reached 25.9% when compared to FISH. The rate of false positives in IHC is 15.7% and 25.6% when compared to FISH. Conclusions: This study confirms that, in order to make the correct therapeutic decision, the IHC technique used in the assessment of HER2 status should undergo stringent internal and external quality controls. Technical and interpretative procedures should be standardized according to international recommendations.
ACCESSION #
86435006

 

Related Articles

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics